Fragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Fragile X Syndrome Clinical Trials Market Report Overview
The Fragile X Syndrome clinical trial market research report provides an overview of the Fragile X Syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on Fragile X Syndrome. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Fragile X Syndrome Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Fragile X Syndrome clinical trials market are Europe, North America, the Middle East & Africa, Asia-Pacific, and South & Central America. Of all the clinical trials conducted on Fragile X Syndrome, as of February 2023, most of the clinical trials were conducted in North America.
In the country-wise analysis, The US has the highest number of fragile x syndrome clinical trials, as of February 2023. Israel has the highest average patient enrollment of fragile x syndrome clinical trials, as of February 2023.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the United States has the highest proportion of Fragile X Syndrome to Genetic Disorders clinical trials as of February 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of Fragile X Syndrome to Genetic Disorders clinical trials as of February 2023.
Fragile X Syndrome Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Fragile X Syndrome clinical trials market, download a free report sample
Fragile X Syndrome Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Fragile X Syndrome clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the market, followed by institution.
Fragile X Syndrome Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Fragile X Syndrome clinical trials market, download a free report sample
Fragile X Syndrome Clinical Trials Market - Competitive Landscape
The leading sponsors in the Fragile X Syndrome clinical trials market are F. Hoffmann-La Roche Ltd, Seaside Therapeutics LLC (Inactive), Novartis AG, Zynerba Pharmaceuticals Inc, Shionogi & Co Ltd, and Neuren Pharmaceuticals Ltd. F. Hoffmann-La Roche Ltd has conducted the highest number of Fragile X Syndrome clinical trials by February 2023.
Fragile X Syndrome Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading players in the Fragile X Syndrome clinical trials market, download a free report sample
Fragile X Syndrome Clinical Trials Market Report Overview
Key Regions | Europe, North America, Middle East & Africa, Asia-Pacific, and South & Central America |
Key Countries | The US, The UK, Canada, France, Spain, and Israel |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | F. Hoffmann-La Roche Ltd, Seaside Therapeutics LLC (Inactive), Novartis AG, Zynerba Pharmaceuticals Inc, Shionogi & Co Ltd, and Neuren Pharmaceuticals Ltd |
Segments Covered in the Report
Fragile X Syndrome Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Fragile X Syndrome Clinical Trials Country Outlook (2023)
- The US
- The UK
- Canada
- France
- Spain
- Israel
Fragile X Syndrome Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) about the company
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Seaside Therapeutics LLC (Inactive)
Novartis AG
Zynerba Pharmaceuticals Inc
Shionogi & Co Ltd
Neuren Pharmaceuticals Ltd
Ovid Therapeutics Inc
Anavex Life Sciences Corp
Arcturus Therapeutics Holdings Inc
Autifony Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the Fragile X Syndrome clinical trials market?
The key regions in the Fragile X Syndrome clinical trials market are Europe, North America, the Middle East & Africa, Asia-Pacific, and South & Central America.
-
Which are the key countries in the Fragile X Syndrome clinical trials market?
The key countries in the Fragile X Syndrome clinical trials market are the US, the UK, Canada, France, Spain, and Israel.
-
What are the key sponsor types in the Fragile X Syndrome clinical trials market?
The key sponsor types in the Fragile X Syndrome clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the Fragile X Syndrome clinical trials market?
The leading sponsors in the Fragile X Syndrome clinical trials market are F. Hoffmann-La Roche Ltd, Seaside Therapeutics LLC (Inactive), Novartis AG, Zynerba Pharmaceuticals Inc, Shionogi & Co Ltd, and Neuren Pharmaceuticals Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.